Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q36106006)
Watch
English
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.
scientific article
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
4588282
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26325035%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
title
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
4588282
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26325035%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
author
Lieping Chen
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
4588282
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26325035%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
author name string
Xue Han
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
4588282
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26325035%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
language of work or name
English
0 references
publication date
1 September 2015
1 reference
stated in
Europe PubMed Central
PMC publication ID
4588282
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26325035%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
published in
Journal of Clinical Investigation
1 reference
stated in
Europe PubMed Central
PMC publication ID
4588282
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26325035%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
volume
125
1 reference
stated in
Europe PubMed Central
PMC publication ID
4588282
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26325035%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
issue
9
1 reference
stated in
Europe PubMed Central
PMC publication ID
4588282
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26325035%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
page(s)
3384-3391
1 reference
stated in
Europe PubMed Central
PMC publication ID
4588282
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26325035%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
cites work
Cancer vaccines
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Pembrolizumab for the treatment of non-small-cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Pembrolizumab versus Ipilimumab in Advanced Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Ipilimumab in the treatment of prostate cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Nivolumab in previously untreated melanoma without BRAF mutation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Pidilizumab in the treatment of diffuse large B-cell lymphoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Programmed death ligand-1 expression in non-small cell lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Management of immune-related adverse events and kinetics of response with ipilimumab
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
The PDL1-PD1 axis converts human TH1 cells into regulatory T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Human TH17 cells are long-lived effector memory cells.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
PD-1 on dendritic cells impedes innate immunity against bacterial infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1).
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
CTLA-4 control over Foxp3+ regulatory T cell function
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Inhibitory B7-family molecules in the tumour microenvironment
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Restoring function in exhausted CD8 T cells during chronic viral infection
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Immunosuppressive networks in the tumour environment and their therapeutic relevance
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Cancer immunotherapy: moving beyond current vaccines
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Interferon-γ: an overview of signals, mechanisms and functions
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
B7 family molecules: novel immunomodulators at the maternal-fetal interface
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Cellular responses to interferon-gamma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
CTLA-4: a negative regulator of autoimmune disease.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
CTLA-4 is a second receptor for the B cell activation antigen B7
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 October 2017
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 July 2018
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
2 July 2018
A new addition to the PD-1 checkpoint inhibitors for non-small cell lung cancer-the anti-PDL1 antibody-MEDI4736.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
23 September 2018
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
23 September 2018
B7-H1 determines accumulation and deletion of intrahepatic CD8(+) T lymphocytes.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
23 September 2018
Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
23 September 2018
CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588282
retrieved
21 October 2018
Identifiers
DOI
10.1172/JCI80011
1 reference
stated in
Europe PubMed Central
PMC publication ID
4588282
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26325035%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
PMC publication ID
4588282
1 reference
stated in
Europe PubMed Central
PMC publication ID
4588282
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26325035%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
PubMed publication ID
26325035
1 reference
stated in
Europe PubMed Central
PMC publication ID
4588282
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26325035%20AND%20SRC:MED&resulttype=core&format=json
retrieved
23 February 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
